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Highlights: 60 
• Pain neuroscience education (PNE) is a pain management intervention.  61 
• Little evidence of true individual differences in response to PNE for disability. 62 
• Findings should be interpreted cautiously due to very wide prediction 63 
intervals. 64 




Pain neuroscience education (PNE) is an approach used in the management of 69 
chronic musculoskeletal pain (CMP). Previous reviews on PNE and other pain 70 
interventions, have focussed on mean treatment effects, but in the context of 71 
“precision medicine”, any inter-individual differences in treatment response are also 72 
important to quantify. If inter-individual differences are present, and predictors 73 
identified, PNE could be tailored to certain people for optimising effectiveness. Such 74 
heterogeneity can be quantified using recently-formulated approaches for comparing 75 




conducted a systematic review and meta-analysis on the extracted standard 77 
deviations of baseline-to-follow up change to quantify the inter-individual variation in 78 
pain, disability and psychosocial outcomes in response to PNE. Electronic databases 79 
were searched between 01/01/2002 and 14/06/2018. The review included five 80 
randomised controlled trials (n=428) in which disability outcomes were reported. 81 
Using a random effects meta-analysis, the pooled SD (95% CI) for control group-82 
adjusted response heterogeneity to PNE was 7.36 units /100 (95% CI: -3.93 to 83 
11.12). The 95% prediction interval for this response heterogeneity SD was wide (-84 
10.20 to 14.57 units /100). The control group-adjusted proportion of “responders” in 85 
the population who would be estimated to exceed a clinically important change of 86 
10/100 ranged from 18-45%. Therefore, when baseline-to-follow up random 87 
variability in disability is taken into account (informed by the control arm), there is 88 
currently insufficient evidence for the notion of clinically important inter-individual 89 
differences in disability responses to PNE in people with CMP. The protocol was 90 
published on PROSPERO (CRD42017068436).  91 
 92 
Perspective 93 
We bring a novel method to pain science for calculating inter-individual differences in 94 
response to a treatment. This is conducted within the context of a systematic review 95 
and meta-analysis on PNE. We highlight how using erroneous methods for 96 
calculating inter-individual differences can drastically change conclusions when 97 
compared to appropriate methods. 98 
Key words 99 







Pain neuroscience education (PNE) is an educational approach used in the 104 
management of chronic pain. PNE aims to reconceptualise an individuals’ 105 
understanding of their pain as less threatening to facilitate rehabilitation23. Since its 106 
inception PNE has become increasingly popular in clinical practice24. Our group 107 
recently published a mixed-methods systematic review and meta-analysis on the 108 
effectiveness of PNE for adults with chronic musculoskeletal pain (CMP)39. 109 
Quantitatively we found no evidence to indicate that PNE results in clinically 110 
important changes over control for pain or disability. In contrast we found moderate 111 
quality evidence that PNE produces small clinically important changes over control 112 
for pain catastrophising and kinesiophobia. Qualitatively we found that achieving 113 
some degree of pain reconceptualisation following PNE can enhance peoples’ ability 114 
to cope with their condition.  115 
 116 
One question that arose during our previous research work was whether PNE may 117 
be effective for some types of people, implying that there may be some individual 118 
differences in response to PNE39. The quantitative component of our review focused 119 
on the mean intervention/treatment effect. This focus on mean intervention effect 120 
whilst common in research on pain interventions5,15,30 could have obscured important 121 
inter-individual differences in response to PNE16,41. Such response heterogeneity is 122 
particularly important within the context of precision medicine, an increasingly 123 
popular field which encompasses ‘tailor-made’ therapies based on the person’s 124 
individual response to a given intervention31. This individualised approach to 125 




importance of a tailored approach has been highlighted by some of our previous 127 
qualitative work on PNE. The relevance of PNE to the individual (i.e. how tailored the 128 
material is to that individual) appears to be an important factor in the success of 129 
PNE17,18,29,39. Where PNE was reported to be relevant, people reported greater 130 
perceived benefit. The opposite was found where PNE was deemed not 131 
relevant17,18,29. 132 
 133 
Some researchers27 have attempted to complement the quantification of mean 134 
treatment effects with a quantification of how many people in each intervention group 135 
change above or below a pre-set threshold, termed sample responder counts. 136 
Crucially, this approach does not provide any information about response 137 
heterogeneity to a given intervention in the context of precision medicine. In fact, 138 
these responder counts lack statistical power and may merely reflect within-subject 139 
random variation between timepoints and/or group differences in mean change. 140 
Furthermore, the dichotomisation (responder or non-responder) also creates 141 
problems adjusting for baseline differences between study groups (comprehensive 142 
reviews are available 2,32). These sample responder counts tell us little about 143 
whether different people respond to different degrees to the same intervention, which 144 
is one of the fundamental questions in precision medicine. Should any inter-145 
individual differences be falsely identified using the above-mentioned methods, any 146 
follow-up analysis to explore potential moderators of the intervention effect to explain 147 
the individual differences in response are therefore unwarranted1,2. Subsequent 148 
follow-up studies on the same participants is a waste of resources, and potentially 149 





Inter-individual differences in response can be quantified by comparing the SDs of 152 
the baseline-to-follow-up changes between the experimental and control groups1,4. 153 
The difference between these SDs represents the SD for individual responses (SDir) 154 
which quantifies the individual variability in treatment response per se. The SD of the 155 
mean change score solely for the intervention group comprises treatment response 156 
variance in addition to the random variability in measurements between the baseline 157 
and follow-up timepoints. The SD of the changes in the control group represents this 158 
random variability in measurements between baseline and follow up – the random 159 
within-subjects variance component and measurement error.  160 
 161 
Our qualitative analysis highlighted that PNE may be effective for some people but 162 
not for others implying that true inter-individual differences in response to PNE may 163 
exist which could be explored to facilitate appropriate targeting of PNE to those most 164 
likely to benefit39. However, clinically relevant inter-individual response variation 165 
should first be conducted using appropriate methodology1,2,13,40,41 to confirm the 166 
presence of such inter-individual responses. If individual differences are observed, 167 
and predictors of individual response are identified, then PNE could be tailored to the 168 
individual optimising its effect41.  169 
 170 
To date, there has been no investigation of ‘true’ individual response variation of the 171 
effect of PNE, or indeed any pain management intervention. Therefore, we aimed to 172 
conduct a systematic review and meta-analysis of the available research to quantify 173 
the ‘true’ inter-individual variation in pain, disability and psychosocial outcomes in 174 







The protocol for the systematic review was published on PROSPERO 179 
(CRD42017068436). The analysis of inter-individual differences is presented here in 180 
detail to ensure the background and rationale for this novel method within the field of 181 
pain is adequately reported. A detailed account of the full review-methods has been 182 
published elsewhere39 but a brief summary is provided below. 183 
Inclusion and Exclusion Criteria  184 
 185 
Inclusion criteria 186 
 187 
• Studies including adults (≥18 years) who have CMP consistent with the British 188 
Pain Society definition (chronic pain, that lasts beyond the time that tissue 189 
healing would normally be expected to have occurred, often taken as ≥3 190 
months)35. 191 
• RCTs that (i) compared the intervention with no treatment (true control) or 192 
usual care (ii) concomitant studies where PNE was delivered in addition to 193 
another intervention where that other intervention was received by both 194 
groups and (iii) head-to-head studies where PNE was compared to another 195 
active intervention. 196 
• Studies reporting either pain and/or disability and/or psychosocial wellbeing. 197 
• The SD of the changes for the intervention and control groups must have 198 
been included within the publication, have been available from the author 199 




standard error. This is an additional criterion that was not included in the 201 
registered protocol.  202 
 203 
Exclusion criteria 204 
 205 
• Studies that included participants with non-musculoskeletal pain such as 206 
cancer pain, visceral pain or post stroke pain.  207 
 208 
 209 
Search Strategy 210 
 211 
Pre-identified keywords (Pain AND (Physiology OR Neurophysiology OR 212 
Neuroscience OR Biology) AND Education) and index terms were searched across 213 
all included databases (The Cochrane Library, AMED, CINAHL Complete, 214 
MEDLINE, PsycINFO, PEDro, Scopus, EMBASE, Education Resources Information 215 
Centre (ERIC), Web of Science, clinicaltrials.gov, dissertations indexed with 216 
ProQuest Dissertations and Theses Global and EThOS) from 2002-25 July 2017, 217 
and updated on 14 June 2018. 218 
 219 
After removing duplicates, the title and abstracts were screened by two authors and 220 
disagreements were resolved through discussion or a 3rd reviewer. The full-text was 221 
obtained for all records that could potentially fit the criteria. Upon reading the full-222 
texts those deemed not to meet the inclusion criteria were rejected. See 223 
Supplementary Digital Content 1 for a list of excluded publications and reasons for 224 






Deviation from protocol 228 
 229 
In our previous review39 when the SD of change was not reported, and could not be 230 
obtained by contacting the authors, it was either calculated from other information 231 
given such as standard error, or estimated from the baseline and follow up SDs, 232 
according to methods described in the Cochrane handbook10. Where there was 233 
uncertainty regarding the validity of baseline, follow up and change score SDs from 234 
included studies we opted not to use this data to inform our calculations to estimate 235 
the SD of change scores. Instead, we used a robust data set of individuals with CMP 236 
where we were confident in the validity of the baseline, follow up and change score 237 
SDs. However, for the current review, given that to calculate the true inter-individual 238 
differences in response to an intervention the SD of the mean change score is of 239 
central importance1, it would be inappropriate to estimate the SD of the change or 240 
use a robust data set. Thus, an additional criterion for inclusion was created for the 241 
current review where the SD of the changes for the intervention and control groups 242 
must have been published in the article, available upon request by the author, or 243 
could be calculated from other information given, such as the standard error.  244 
 245 
Assessment of methodological quality and data extraction 246 
 247 
Articles selected for critical appraisal were independently assessed by two reviewers 248 
using the Cochrane tool for assessing risk of bias9. Two reviewers independently 249 




populations, study methods and outcomes of relevance to the review 251 
question/objectives. The Grades of Recommendation, Assessment, Development 252 
and Evaluation (GRADE) approach7 was used to rate the overall quality of 253 
quantitative evidence for each outcome. A summary of findings table created using 254 




To contextualise the results for individual response variance we conducted a 259 
random-effects meta-analysis for the mean difference in disability across the 260 
included studies using a restricted maximum likelihood (REML) model combined with 261 
the Knapp-Hartung method. This method uses quantiles of the t distribution to 262 
calculate a confidence interval for the average effect instead of the standard normal 263 
distribution in the more conventional methods37 . The Knapp-Hartung method has 264 
been shown to be superior to the DerSimonian-Laird method where there is a small 265 
number of studies (<20) and heterogeneity is present11. We then extracted the 266 
standard deviation of the changes in disability for both control (C) and PNE (I) 267 
groups. The true individual response variance (intervention minus control) was then 268 
calculated by √(SDI2-SDC2)13. The standard error (SE) for this variance was then 269 
calculated using the equation: SE = √[2(SDI4/DFI + SDC4 /DFC )], where DFI and DFC 270 
are the degrees of freedom of the standard deviation in the PNE group and the 271 
control groups13. A negative value for the individual response variance for the 272 
confidence intervals or prediction intervals implies greater variability in the changes 273 





The individual response variances and their SEs were meta-analysed using an 276 
REML model combined with Knapp-Hartung method. It’s important to highlight that 277 
the variances are unbiased, whereas the SD is not, and deriving a SE for the SD for 278 
individual responses is also problematic. Thus, we synthesised the individual 279 
response variances instead of the SDs for individual responses. The point estimate 280 
for the pooled individual response variance were derived together with a 95% CI to 281 
express its uncertainty. The point estimate and CIs were then square rooted to 282 
convert to an SD metric. If the lower limit was negative, the sign was ignored, the 283 
square root taken, and the sign re-applied. This approach is consistent with the ‘no 284 
bound’ option in SAS/STAT® software, which permits negative variances (SAS 285 
Institute Inc. 2017. SAS/STAT 14.3 User’s Guide. Cary, NC: SAS Institute Inc.). 286 
 287 
Using the methods of Swinton et al.34 the proportion of responders in the population 288 
of interest within each included RCT was estimated. To estimate this, the observed 289 
mean change score and true individual response variance are needed for each RCT. 290 
Normal variance is assumed. The total area of any probability distribution is equal to 291 
one, thus the estimate of the proportion of response can be obtained by calculating 292 
the area of the derived normal distribution that lies beyond the minimally clinically 293 
important difference (MCID). An MCID of 10% was used in recent NICE guidelines 294 
for back and radicular pain25. The calculation estimating the proportion of response 295 
was performed via an online calculator28. The proportion of response was estimated 296 
for the intervention and control groups for all RCTs and has been used to 297 
demonstrate the difference in results, and thus conclusion that could be made if 298 





The tau statistic (τ) was used to quantify between-study heterogeneity – a SD that 301 
describes the typical variability of the mean effect between studies3,8. A 95% 302 
prediction interval was calculated using the tau and the SE for the pooled mean 303 
effect to quantify the expected range of true effects in future similar studies12. Stata 304 
(StataCorp. 2019. Stata Statistical Software: Release 16. College Ststion, TX: 305 




Following removal of duplicates, 12,136 publications were identified (Fig. 1). Fifty-310 
seven full text articles were screened. Forty-nine articles were excluded at this stage. 311 
See document, supplementary digital content 1 for a list of excluded publications and 312 
reasons for exclusion. Thus, six publications reporting five RCTs were 313 
included6,19,20,21,26,38. The included studies encompassed a total of 428 participants (I 314 
= 212, C = 216). Table 3 provides further details regarding the studies.   315 
 316 
 317 
Methodological quality  318 
 319 
Quality scores ranged from 1-6 out of 7 (Table 4). There was a high risk of 320 
performance bias due to lack of blinding of participants and personnel (Fig. 2 and 3 321 
produced by using RevMan software (Review Manager. Version 5.3. Copenhagen: 322 







Study outcomes 327 
 328 
Jackson and Turner14 recommend only pooling data where the number of studies is 329 
≥5 to ensure adequate statistical precision. Disability was the only outcome 330 
measured consistently in all five included studies, thus our analysis focused solely 331 
on this outcome.  332 
 333 
The pooled mean group difference in pre/post changes in disability (intervention 334 
minus control) was -2.26 units /100 (95% CI: -6.49 to 1.97). See Fig. 4. Between 335 
study heterogeneity in mean treatment effect was observed (τ = 2.49; 95% CI: 0.48 336 
to 4.51). The prediction interval revealed that, were investigators to undertake a 337 
future trial, the 95% plausible range for mean disability change versus control would 338 
be -11.56 to 7.04 units /100.  339 
 340 
The pooled point estimate for the inter-individual variability in disability change in 341 
response to PNE (SDIR) was 7.36 units /100 (95% CI: -3.93 to 11.12). Substantial 342 
between-study heterogeneity was observed (τ = 6.55). The 95% prediction interval 343 
for true inter-individual responses was -10.20 to 14.57. Appendix 1 provides a step 344 
by step guide for the calculations here.  345 
Using the methods of Swinton et al.34 we estimated the proportion of responders in 346 
the population of interest within each included RCT (Table 5). The threshold 347 
reduction in disability for clinical relevance was set at -10/100, in keeping with recent 348 




the apparent proportions exceeding this threshold in the comparator groups that 350 
were estimated to be due wholly to random variability in the pre to post 351 
measurements of disability. It can be seen that these proportions are generally lower 352 
than the proportion of participants who exceed the threshold in the intervention 353 
groups per se. 354 
 355 
Discussion  356 
We conducted a systematic review and meta-analysis of the literature in order to 357 
quantify the control-group adjusted inter-individual variation in pain, disability and 358 
psychosocial outcomes in response to PNE in adults with CMP. Several potential 359 
studies did not report the SD of the mean change, and this information could not to 360 
be obtained upon request meaning our analysis was restricted to disability. 361 
 362 
The inter-individual difference in disability change in response to PNE, as indicated 363 
by our SDir of 7.36 /100 units, did not reach our criterion for clinical significance (10 364 
/100 units). Therefore, there is insufficient evidence at present for the existence of 365 
inter-individual differences in people’s response to PNE over and above random 366 
within-subjects variability between baseline and follow-up observations. Although this 367 
finding, seems at odds with previous qualitative study findings from our group17,18,29, 368 
that qualitative work focused upon patient experience rather than attempting to 369 
objectively quantify inter-individual differences.  Considering the upper 95% CI 370 
(11.12 /100 units) and wide 95% prediction interval -10.20 to 14.57 of the SDir, any 371 
inferences regarding “true” inter-individual responses are unclear. Given the small 372 




illustrates the importance of statistical power in any analysis of response 374 
heterogeneity1,2. 375 
 376 
Therefore, it is apparent that more high quality RCTs are needed that sufficiently 377 
report relevant data. We encourage researchers and reviewers of academic journals 378 
to ensure that the means and standard deviations of the change scores in all 379 
treatment groups are reported. This will provide the information required to include 380 
the study within meta-analyses of both individual responses and mean effect of 381 
treatment.  382 
It is worth highlighting that the very common act of simply looking at the intervention 383 
group responses (Table 4) would have falsely led a researcher to think that 384 
substantial response heterogeneity was present. This may have led to follow-up 385 
analyses to explore potential moderators which may be unwarranted and a waste of 386 
resources. Furthermore, any follow-up studies on the same participants may be 387 
unethical if there are no true individual differences in response present to explain1. 388 
 389 
This is the first systematic review and meta-analysis to employ the method of 390 
calculating true inter-individual differences in response to an intervention within the 391 
pain sciences34. Given the huge global burden of chronic pain, and the limited 392 
efficacy of current treatment options for matching peoples' individual responses to 393 
treatments, appropriate methodology needs to be applied across the pain field. This 394 
will hopefully lead to improved quality of care, reduced costs33 and ultimately 395 







Only five studies were eligible for this review which meant that we could only analyse 400 
disability data and the inter-individual differences in response to PNE for other 401 
outcomes are unknown. Six studies that were otherwise eligible, were excluded 402 
because they did not report the appropriate data needed to conduct an inter-403 
individual differences meta-analysis and this data was not available upon email 404 
request. We have no reason to believe that authors would withhold this data and 405 
thus assume these studies are missing at random. Only studies published in English 406 
were eligible for inclusion as no facility for translation was available. Thus, important 407 
data from non-English studies may have been missed.  408 
 409 
The nature of the comparison group will influence the calculation of the inter-410 
individual difference. In the case of usual care comparisons and other intervention 411 
comparisons, if these have inherent variability in response within them, beyond 412 
random variability (noise) of a true no intervention control, this may mask the degree 413 
of interindividual variability seen within the PNE (intervention of interest) group. 414 
Thus, this could have influenced the findings. Nevertheless, in the case of 415 
intervention vs usual care, if there are true individual differences in the responses to 416 
the novel component(s) of the intervention under study, then this should, in theory, 417 








This is the first study to investigate “true” inter-individual differences in response 423 
within the field of pain. By this, we mean a quantification of response heterogeneity 424 
that takes into account the individual differences in baseline to follow-up change that 425 
can be observed in the comparator groups, and are attributable to random fluctuation 426 
in pain scores over time. Our findings provide little evidence at present of “true” 427 
variation in peoples’ response to PNE regarding disability, but the evidence is very 428 
uncertain. Furthermore, given the wide 95% confidence and prediction intervals any 429 
inferences made regarding true individual variation in peoples’ response to PNE are 430 
unclear. Moreover, given the small number of studies included in the analysis further 431 
work is warranted before firm conclusions can be drawn. Therefore, the data 432 
currently available does not allow us to clearly identify if individual differences in 433 
disability occur for people with CMP following PNE. We would recommend against 434 
studies exploring which factors may explain which people will benefit from PNE until 435 
such time as the existence of inter-individual differences has been confirmed using 436 
appropriate methodology and we would extend this recommendation to all pain 437 
interventions.  438 
 439 
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Table 1 Summary of findings:  
PNE compared to control for treatment of adults with chronic musculoskeletal pain 
Patient or population: treatment of adults with chronic musculoskeletal pain  
Setting:  
Intervention: PNE  
Comparison: control  
Outcomes 
Anticipated absolute effects* 
(95% CI)  Relative 
effect 















































PNE may reduce/have little to no 
effect on change in disability 
score in the short term. but the 
evidence is very uncertain.  
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the 
relative effect of the intervention (and its 95% CI).  
 
CI: Confidence interval  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, 
but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the 
effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the 
estimate of effect  
Explanations 595 
a. A large proportion of the weight came from a study where there was concern over selection bias, performance bias, attrition bias, 596 
reporting bias and other bias. There was concern with most studies over performance bias which whilst normal of these types of studies may 597 
still impact the results.  598 
b. Some variation is size of the effect, however the difference between studies does not reach a clinically meaningful difference  599 
c. Good overlap of the confidence intervals.  600 
d. I-Squated above 50%  601 
e. Tau-Squared higher than point estimate.  602 
f. Sample of chronic musculoskeletal pain comparing PNE against control using an appropriate outcome measure.  603 
g. Has over 400 participants but imprecise due to prediction interval including null effect and clinically important benefit.  604 
h. A comprehensive search was conducted on electronic databases and trials registries. References lists and citing articles of included studies 605 
were searched to identify any further articles.  606 
 607 
Table 1 Legend: Summary of findings, PNE compared to control for treatment of 608 





Table 2 Summary of findings:  
Do inter-individual differences in disability change in response to PNE exist in adults with 
chronic musculoskeletal pain? 
Patient or population: treatment of adults with chronic musculoskeletal pain  
Setting:  
Intervention: PNE  




individual difference in 
response (95% CI) 
№ of participants  
(studies) 







change in the 







Scale from: 0 to 
100 (worse) 
mean 7.36 units 






Little evidence of “true” 
variation in peoples’ response to 
PNE for disability, but the 
evidence is very uncertain. 
CI: Confidence interval  
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true difference in response lies close to that of the estimate of the difference in response  
Moderate certainty: We are moderately confident in the difference in response estimate: The true difference in response is likely to be 
close to the estimate of the difference in response, but there is a possibility that it is substantially different  
Low certainty: Our confidence in the difference in response estimate is limited: The true difference in response may be substantially 
different from the estimate of the difference in response 
Very low certainty: We have very little confidence in the difference in response estimate: The true difference in response is likely to be 
substantially different from the estimate of difference in response 
Explanations 611 
a. A large proportion of the weight came from a study where there was concern over selection bias, performance bias, attrition bias, 612 
reporting bias and other bias. There was concern with most studies over performance bias which whilst normal of these types of studies may 613 
still impact the results.  614 
b. Some variation in size of the effect, however the difference between studies does not reach a clinically meaningful difference  615 
c. Good overlap of the confidence intervals.  616 
d. Tau-Squared higher than point estimate.  617 
e. Sample of chronic musculoskeletal pain comparing PNE against control using an appropriate outcome measure.  618 
f. While the analysis includes over 400 participants this lack precision due to the very wide prediction interval including both a clinically 619 
important positive effect and clinically important negative effect.  620 
g. No evidence of publication bias. Sample sizes ranged from 62-120. A comprehensive search was conducted on electronic databases and 621 
trials registries. References lists and citing articles of included studies were searched to identify any further articles.  622 
 623 
Table 2 Legend: Summary of findings, Do inter-individual differences in disability 624 






Table 3 Characteristics of included studies 628 
 629 






Participants  Intervention(s) Duration of 
educational 
intervention 















18-65 years of 
age. 
 
Baseline pain as 
mean % = 71.5% 
Duration of pain in 
mean months = 
unknown 
Written PNE + 1 phone 
call for 
motivation/questions +/- 




Unknown Written Relaxation 
exercises + 1 phone 
call for 
motivation/questions 
+/- 2x phone 
calls/emails for further 
clarification/questions 
 
Written PNE alone is not 
effective for changing the 
impact of the illness on daily 
life, pain catastrophising, or 
illness perceptions in 









RCT N = 79 
39% M 
18-75 years of age 
with pain that had 
80-page booklet divided 
into 11 sections - 
Unknown 80-page booklet 
divided into 11 
Written material using 









43.5 been sufficient to 
disrupt their 
activities of daily 
living for more 
than the previous 3 
months. 
 
Baseline pain as 
mean % = 65% 
 
Duration of pain in 
mean (SD) months 
= 28 (19.5) 
Metaphors and stories to 
help understand the 
biology of pain 
 
sections - Advice about 
managing pain (The 
back book and Manage 
your pain) 
 
biological concepts increased 
knowledge of pain biology and 
decreased catastrophic thought 
processes about pain and injury 
when compared to material that 
presented biopsychosocial 




RCT N = 62 
35% M 
51 
Low back pain >3 
months duration 
+/- leg pain. 18-65 
years of age. 
 
Baseline pain as 
mean % = 42.9% 
 
Duration of pain in 
mean (SD) months 
= unknown 
2x 1.5h Group PNE.  
12 sessions of aquatic 
exercise over 6 weeks. 






12 sessions of aquatic 
exercise over 6 weeks. 
30-50m each session. 
 
PNE is a clinically effective 
addition to aquatic exercise. 
The addition of PNE resulted in 
statistically significant reduction 
in pain intensity at 3-month 
follow up. No statistically 
significant differences were 
found for pain intensity at 6 
weeks follow up or functional 




Louw et al. 
2014/1619,20 




0.5h individual PNE. PNE 0.5h 
 
Lumbar surgery alone 
+ usual care 
Providing a single PNE session 
to patients prior to lumbar 
7 Clinical sites 







18-65 years of 
age. 
 
Baseline pain as 
mean % = 48.4% 
 
Duration of pain in 
mean (SD) months 
= 3 (7.5) 
PNE booklet "your 
nerves are having back 
surgery" & Lumbar 
surgery + usual care 
 
Control 0  surgery results in significant 
reduction in healthcare costs 3-
years after LS.   
Malfliet et 
al. 201821 




chronic spinal pain 
(neck and lower 
back) at least 3 
days a week for at 
least 3 months 
since the first 
symptoms.  
 
18-65 years of age 
 
Baseline pain as 
mean % = 50.65 
 
3 PNE sessions 
1. 0.5-1h group 
(maximum of 6 
patients). 
Information booklet 
provided at the 
end. 









3 biomedical education 
sessions 
1. 0.5-1h group 










PNE, and not neck/back school 
education, is able to improve 
kinesiophobia, beliefs regarding 
the negative impact of the 
illness on quality of life and 
functional capacity, and beliefs 
regarding the chronicity of pain 
and the time scale of illness 
symptoms. However, none of 
the educational programs of this 
study were able to decrease the 
participants perceived disability 
due to pain. Nevertheless, as 










Duration of pain in 
mean (SD) months 
= 82 (143.25) 
questions about 
pain.  
3. 0.5 Individual 




session 2. Focus on 
the application of 
knowledge to 
participants life. 
3. 0.5 Individual. 




session 2. Focus 
on the application 
of knowledge to 
participants life. 
considered to be a strong 
predictor and mediator of 
chronic pain, PNE is preferred 
as the educational approach for 
people with non-specific 
chronic spinal pain.  
 630 
Table 3 Legend: Randomized controlled trial, RCT. Male, 631 
 632 
 633 
Table 3 Legend: Characteristics of included studies. PNE, Pain neuroscience education. SD, Standard deviation. RCT, 634 





Table 4 Critical appraisal of quantitative studies 637 
Study Score /7 Percentage 
Gallager 20136 5 71% 
Louw 2014/1619,20 3 43% 
Malfliet 201821 6 86% 
Pires 201526 3 43% 
van Ittersum 201338 1 14% 
Figure 4 Legend: Forest plot of PNE versus control in the short term; primary 638 
outcome disability mean difference. 639 
 640 
 641 
Table 5: Proportions of responders. 642 
Table 5 Legend: Proportions of responders. PNE, Pain neuroscience education. 643 





































201526 -11.1 15.8 53 -7.7 10.6 41 -3.4 11.7 
29 
Louw et al. 





















Figure 1 Legend: PRISMA flow diagram of search and study selection process. 647 

























Records identified through 
database searching 
























Additional records identified 
through other sources 
(n = 1) 
Records after duplicates removed 
(n = 12’136) 
Records screened 
(n = 12’136) 
Records excluded 
(n = 12’079) 
Full-text articles assessed 
for eligibility 
(n = 57) 
Full-text articles excluded, with reasons 
(n = 51) 
 
1. Conference abstract only (n=8) 
2. Published trial already included (n=2) 
3. Mean duration of pain <3 months (n=1) 
4. Not appropriate study type (n=6) 
5. Not PNE (n=16) 
6. Not an RCT or qualitative design (n=4) 
7. Protocol (n=1) 
8. Author reports paper not written (n=6) 
9. SD of the mean change score for the 
intervention and control groups could 
























Figure 4 Legend: Forest plot of PNE versus control in the short term; mean 657 











        Supplementary Appendix 1 - Calculations for inter-individual differences meta-analysis
Step 1
Study SDC Mean I






Study IR_Variance SDI SDC
van Ittersum 9.23 4.2 2.9
Gallagher 64 17 15
Pires 137.28 15.8 10.6
Louw 152.09 18.5 13.79
Malfliet 65.84 13.79 11.15
Step 3
Study IR_Variance SE SDI SDC n I n C
van Ittersum 9.23 3.83949378 4.2 2.9 53 52
Gallagher 64 83.3522758 17 15 40 39
Pires 137.28 71.5013373 15.8 10.6 30 32
Louw 152.09 103.087047 18.5 13.79 29 33
Malfliet 65.84 41.8303551 13.79 11.15 60 60
Step 4
 Forest plot of Variance Meta-analysis for estimating individual differences in response:
We extracted the standard deviation (SD) of the changes in disability for both control (C) and 
PNE (I) groups.




The standard error (SE) for this variance was then calculated using the equation:                            
SE = √[2(SD I4/DFI + SDC4 /DFC )], where DF I and DFC are the degrees of freedom of the 
standard deviation in the PNE group and the control groups (Hopkins, 2015).
The individual response variances and their SEs were meta-analysed using an REML model 
combined with Knapp-Hartung method. It’s important to highlight that the variances are 
unbiased, whereas the SD is not, and deriving a SE for the SD for individual responses is also 
problematic. Thus, we synthesised the individual response variances instead of the SDs for 
individual responses. The point estimate for the pooled individual response variance were 
derived together with a 95% CI to express its uncertainty.
Step 5
As variance SD without sign
As SD with 
sign re-
applied
Total point estimate 54.14 7.35798886
Lower CI - 15.42 3.92683078 -3.9268308
Upper CI 123.69 11.1216006
Steps to calculate the prediction interval for the inter-individual differences point estimate





SE2 = 627.543743 (From STATA)
tau2  = 1841.4235
(SE2 + tau2) = 2468.96724
SQRT(SE 2 + tau2) = 49.6887034
PI = Pooled est +/-  t(n-2) x SQRT(SE2 + tau2)
PI = 54.14 +/- 3.182 x 49.6887034
PI = 3.182 +/- 158.109454
3.182 is the two-tailed t value for n-2 degrees of 
freedom = 3 degrees of freedom, and P=0.05. See: 
http://www.ttable.org/student-t-value-
calculator.html
The point estimate and CIs were then square rooted to convert to an SD metric. If the lower 
limit was negative, the sign was ignored, the square root taken, and the sign re-applied. This 
approach is consistent with the ‘no bound’ option in SAS/STAT® software, which permits 
negative variances (SAS Institute Inc. 2017. SAS/STAT 14.3 User’s Guide. Cary, NC: SAS 
Institute Inc.).
PI Upper = 212.249454
PI Lower = -103.96945
Square root the above values to convert from variance to SD to get to the PI for the SDir:
PI Upper = 14.5687836
PI Lower = -10.196541
